论文部分内容阅读
全球范围生产和销售变应原疫苗,用来诊断和治疗IgE抗体介导的疾病。变应原疫苗是天然物质的混合物。每一种变应原提取物含有蛋白质、碳水化合物、酶、色素等物质,其中,具有变应原活性的物质只占一小部分。传统的变应原疫苗用投料比(重量/体积)标示疫苗,也有用凯氏定氮法测定蛋白氮标示疫苗,但是这两种标示疫苗的方法与疫苗的活性没有必然的关系。缺乏一致的方法来维持产品的一致性,疫苗批与批之间多样化是显然的。所以变应原疫苗的标准化是必须和必然的。变应原疫苗的标准化主要通过建立内部参考品,从变应原疫苗总蛋白组分、总蛋白含量、主要致敏蛋白的组成、主要致敏蛋白的含量、体内体外实验测定总活性这几个方面,每批产品与内部参考品相比较,达到产品批与批之间的一致性。在美国和欧洲的变应原标准化存在一定的差异,本文从美国和欧洲变应原疫苗的标准化历程介绍变应原疫苗标准化的方法和发展趋势。
Allergen vaccines are manufactured and marketed globally to diagnose and treat IgE antibody-mediated diseases. Allergen vaccines are mixtures of natural substances. Each allergen extract contains proteins, carbohydrates, enzymes, pigments and other substances, of which allergen-containing substances account for only a small part. Conventional allergen vaccines are labeled with the ratio (w / v) of the vaccine, and the protein nitrogen-labeled vaccine is also determined by the Kjeldahl method, but the two methods of labeling the vaccine are not necessarily related to the activity of the vaccine. Lack of a consistent approach to product consistency is evident in the diversification of vaccine batches and batches. Therefore, the standardization of allergen vaccines is necessary and necessary. The standardization of allergen vaccines mainly through the establishment of internal reference materials from the total allergen vaccine protein composition, the total protein content, the composition of the main allergenic protein, the main allergenic protein content, in vivo and in vitro experiments to determine the total activity of these Aspects, each batch of products compared with the internal reference to achieve the consistency between product batch and batch. There are some differences in the standardization of allergens in the United States and Europe. In this paper, the standardization methods and development trends of allergen vaccines are introduced from the standardization process of allergen vaccines in the United States and Europe.